A phase I dose-escalation study of IMAB362 (Zolbetuximab) in patients with advanced gastric and gastro-oesophageal junction cancer

Şahin, Uğur; Schüler, Martin; Richly, Heike; Bauer, Stefan; Krilova, Anna; Dechow, Tobias; Jerling, Markus; Utsch, Magdalena; Rohde, Christoph; Dhaene, Karl; Huber, Christoph; Türeci, Özlem

doi:10.1016/j.ejca.2018.05.007

Public

A phase I dose-escalation study of IMAB362 (Zolbetuximab) in patients with advanced gastric and gastro-oesophageal junction cancer

Published in European Journal of Cancer • Jun 21, 2018

Authors:

Uğur Şahin

Martin Schüler

Heike Richly

Abstract

IntroductionIMAB362 (Zolbetuximab) is a chimeric monoclonal antibody that binds to Claudin-18.2, a target antigen specific to cancer cells. In vitro, IMAB362 mediates cell death through antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity; thus, IMAB362 may serve as a poten...

Subject

Tolerability

Medicine

Pharmacokinetics

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!